ViaCyte has received a $10.1m strategic partnership award from the California Institute for Regenerative Medicine (CIRM) to develop VC-01, which is a regenerative medicine, consisting of pancreatic beta cell progenitors in a durable ...
Tags: ViaCyte, Diabetes Therapy Development, CIRM